U.S. markets closed

NexPrise, Inc. (NXPS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00010.0000 (0.00%)
At close: 3:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0001
Open0.0001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0001 - 0.0001
52 Week Range0.0001 - 0.0001
Volume42
Avg. Volume0
Market Cap320
Beta (5Y Monthly)-387.14
PE Ratio (TTM)N/A
EPS (TTM)-3.6380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
    Business Wire

    DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021

    DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Dermatology Summit virtual conference (the "Dermatology Summit") on Jan. 8, 2021. The Dermatology Summit uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.

  • DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry
    Business Wire

    DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry

    DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic atypia using DermTech’s Pigmented Lesion Assay (the "PLA") may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions.

  • Business Wire

    DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines

    DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-invasive genomic patch testing for melanoma, like DermTech’s Pigmented Lesion Assay ("PLA"), has received a recommendation from the National Comprehensive Cancer Network® ("NCCN"). The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice Guidelines in Oncology (the "NCCN Guidelines®") for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.